Desotop Gel
Desonide Topical
0.05%
ACI Limited
| Pack size | 15gm tube |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 50.34 AED |
Indications
Desotop Gel is used for:
Psoriasis, Eczema, Contact dermatitis, Corticosteroid-responsive dermatoses, Seborrheic dermatitis
Adult Dose
Topical/Cutaneous
Corticosteroid-responsive dermatoses
Adult: Apply sparingly onto the affected areas 2 times/day.
Discontinue therapy when control is achieved.
If no improvement seen within 4 weeks, reassessment of diagnosis may be necessary; treatment beyond 4 consecutive weeks not recommended.
Child Dose
Dermatoses
<3 years: Safety and efficacy not established
>3 years: Apply gel sparingly to affected area(s) q8-12hr; discontinue therapy if control achieved
Renal Dose
Administration
For topical use only. Not for oral, ophthalmic, or intravaginal use.
Contra Indications
Hypersensitivity to any of the components. Primary infective skin conditions.
Precautions
Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids
Use medium-to-very high potency topical corticosteroids for <2 wk to reduce local and systemic adverse effects; avoid use on face, folds, groin owing to increased absorption
Use low-potency topical corticosteroids for chronic therapy
May cause local skin adverse reactions; if irritation develops, discontinue treatment and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation; corroborate with appropriate diagnostic patch testing
If concomitant skin infections are present or develop, initiate appropriate antifungal, antibacterial, or antiviral agent; if favorable response does not occur promptly, discontinue desonide until infection controlled
Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma
Avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation
Because of potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression; factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure
An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression; if HPA axis suppression documented, an attempt should be made to gradually withdraw drug, to reduce frequency of application, or to substitute a less potent steroid; manifestations of adrenal insufficiency may require supplemental systemic corticosteroids; recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids
Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure
Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids
Pregnancy-Lactation
Pregnancy
There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Lactation
There are no data on presence in human or animal milk, effects on breastfed infant, or on milk production; unknown whether topical administration could result in sufficient systemic absorption to produce detectable quantities in human milk; developmental and health benefits should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition
To minimize potential exposure to breastfed infant via breast milk, use on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women to wash off any amount that may have been applied to nipple and areola prior to breastfeeding to avoid direct infant exposure
Interactions
Adverse Effects
Side effects of Desonide Topical :
Frequency Not Defined
Skin atrophy
Striae
Hypertension
Headache
Irritability
Hyperglycemia
Itching
Scaly skin
Acneform lesions
Pigmentation changes
HPA suppression (with higher potency used >2 wk)
Mechanism of Action
Desonide is a corticosteroid used mainly for its glucocorticoid activity in the treatment of various skin disorders.
Note
Desotop 0.05% Gel manufactured by ACI Limited. Its generic name is Desonide Topical. Desotop is availble in Bangladesh.
Farmaco BD drug index information on Desotop Gel is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.